CEO Doug is a LIAR, wants his WARRANTS Exercised,in Feb 2022His trial is dated to 2027 when he will ROOST with JUVA Insiders, share price TANKS DAILY.
The Company’s business focus is the development of safe and effective treatments targeting the global anti-inflammatory therapeutics market is estimated to reach USD $191.4 billion by 2027, as reported by Fortune Business Insights.
ALONG WAIT, not buying this DIRT.